Fedratinib

Drug Profile

Fedratinib

Alternative Names: SAR-302503; TG-101348

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TargeGen
  • Developer Impact Biomedicines; Sanofi
  • Class Phenyl ethers; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myelofibrosis
  • Phase II Essential thrombocythaemia; Polycythaemia vera
  • Discontinued Solid tumours

Most Recent Events

  • 26 Oct 2017 Updated efficacy and adverse events data from the phase II JAKARTA-2 trial in Myelofibrosis released by Impact Biomedicines
  • 13 Oct 2017 Fedratinib licensed to Impact Biomedicines worldwide
  • 13 Oct 2017 Phase-II clinical trials in Essential thrombocythaemia in United Kingdom, Spain, France, Germany, USA, Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top